Your browser doesn't support javascript.
loading
Final report of TKI discontinuation trial with dasatinib for the second attempt of treatment-free remission after failing the first attempt with imatinib: Treatment-free Remission Accomplished by Dasatinib (TRAD) study.
Perusini, Maria Agustina; Novitzky-Basso, Igor; Atenafu, Eshetu G; Forrest, Donna; Bence-Bruckler, Isabelle; Savoie, Lynn; Keating, Mary-Margaret; Busque, Lambert; Delage, Robert; Xenocostas, Anargyros; Liew, Elena; Laneuville, Pierre; Paulson, Kristjan; Stockley, Tracy; Lipton, Jeffrey H; Leber, Brian; Kim, Dennis Dong Hwan.
Afiliação
  • Perusini MA; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Novitzky-Basso I; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Atenafu EG; Department of Hematology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
  • Forrest D; Biostatistic Department, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Bence-Bruckler I; Leukemia/BMT Program of British Columbia, Division of Hematology, Vancouver General Hospital, British Columbia Cancer Agency, and University of British Columbia, Vancouver, British Columbia, Canada.
  • Savoie L; Department of Medicine, University of Ottawa, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
  • Keating MM; University of Calgary, Alberta Health Services, Calgary, Alberta, Canada.
  • Busque L; Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia, Canada.
  • Delage R; Hematopoiesis and Aging Research Unit, University of Montreal, Hôpital Maisonneuve-Rosemont, Montreal, Quebec, Canada.
  • Xenocostas A; Centre Universitaire d'Hématologie et d'Oncologie de Québec, CHU de Québec, Hôpital de l'Enfant-Jésus, Quebec City, Quebec, Canada.
  • Liew E; Division of Hematology, Department of Medicine, London Health Sciences Centre, University of Western Ontario, London, Ontario, Canada.
  • Laneuville P; Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
  • Paulson K; Division of Hematology, McGill University Health Centre, Montreal, Quebec, Canada.
  • Stockley T; CancerCare Manitoba, Winnipeg, Manitoba, Canada.
  • Lipton JH; Department of Pathology, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada.
  • Leber B; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Kim DDH; Department of Hematology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
Br J Haematol ; 203(5): 781-791, 2023 12.
Article em En | MEDLINE | ID: mdl-37697469
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Mielogênica Crônica BCR-ABL Positiva / Inibidores de Proteínas Quinases Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Mielogênica Crônica BCR-ABL Positiva / Inibidores de Proteínas Quinases Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article